Elena V. Rozanсeva

Elena V. Rozanсeva

Auto-generated profile, based on publicly available information

Elena V. Rozanсeva

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ASA. V. Satsuk
A. V. Satsuk
GSGalina Solopova
Galina Solopova
SBS. V. Begunova
S. V. Begunova
ERE. V. Rozantseva
E. V. Rozantseva
APA. A. Ploskireva
A. A. Ploskireva
VAVasily G Akimkin
Vasily G Akimkin
Patients with oncological and hematological diseases are at high risk of acquiring bloodborne infections due to multiple blood transfusions and frequent parenteral exposure. In order to evaluate the prevalence of bloodborne infections (i. e., hepatitis B, hepatitis C, and human immunodeficiency virus (HIV)), we analyzed data on the seroprevalence of these viruses in patients admitted to the D. Rogachev NMRCPHOI from 2014 to 2020. We also performed a comparative analysis between these data and the prevalence of these infections in the total child population in Russia. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. Among patients admitted to the D. Rogachev NMRCPHOI, the mean seroprevalence was 1.7% for hepatitis C, 0.2% for hepatitis B, and 0.1% for HIV. The seroprevalence of hepatitis B and C among our patients was 6 and 50 times higher than the prevalence among Russian children and adolescents, respectively. The prevalence of HIV among patients treated at the D. Rogachev NMRCPHOI was 3 times higher than that among the child and adolescent population in Russia. In patients with oncological and immunological diseases, the detection of HBV DNA, HCV RNA, and Anti-HBc is considered clinically useful and plays an important role in the diagnosis of occult hepatitis infections which cannot be identified with routine diagnostic tests. Our study with pediatric patients with oncological, hematological, and immunological diseases highlights the problem of nosocomial transmission of bloodborne pathogens. HCV transmission in medical facilities is the most pressing issue that requires the implementation of healthcare programs aimed at preventing parenteral transmission and at ensuring the safety of donated blood.

21 December 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GSGalina Solopova
Galina Solopova
ETE. V. Tsyganova
E. V. Tsyganova
AKA. V. Kondrashova
A. V. Kondrashova
GGG. N. Gordeeva
G. N. Gordeeva
ERE. V. Rozanceva
E. V. Rozanceva
GNG. A. Novichkova
G. A. Novichkova
Data on clinical manifestations of COVID-19 in immunocompromised patients in Russia is lacking, which prompted us to conduct a study to investigate clinical manifestations, risk factors, and outcomes of SARS-CoV-2 infection in children with oncological and hematological diseases treated at the D. Rogachev NMRCPHOI (Center). In this retrospective-prospective, nonrandomized, non-interventional study we enrolled children under 18 years with cancer, hematologic malignancies, and primary immunodeficiencies (PIDs) who underwent treatment at the Center from April 2020 to October 2021. COVID-19 cases were confirmed by polymerase chain reaction testing and classified as asymptomatic, mild, moderate, severe and critical. The study was approved by the Independent Ethics Committee and the Scientific Council of the Center. The study included 89 patients with a median age of 9.7 years and almost equal gender distribution (the male-to-female ratio was 1.1:1). Most patients (74%) were infected in a family claster. The main underlying diseases were: hemoblastoses (43.8%), solid tumors (33.7%), PIDs (14.6%). The most common clinical symptoms were fever (29%) and respiratory symptoms (47%). In 79% of cases, patients were asymptomatic or had mild symptoms; 21% of patients had moderate and severe disease (16% and 5%, accordingly). Risk factors associated with severe COVID-19 included lymphopenia (p 0.001) and hematopoietic stem cell transplantation (HSCT) (p = 0.002). Full recovery was documented in 84% of the patients, 16% died, however COVID-attributed mortality was 5.5%. The highest mortality was in patients with moderate/severe COVID-19 (47% vs 7%, p 0.001), in those with progression/ relapse of the underlying disease (36.3% vs 6%, p = 0.02), in children who had received specific therapy within a year before the SARS-CoV-2 diagnosis (21% vs 0%, p = 0.02), among HSCT recipients (31.6% vs 12.1%, p = 0.02), and patients with concomitant infections (33% vs 9.2%, p 0.01). Factors associated with poor prognosis were moderate or severe COVID-19, relapse/ progression of the underlying disease, specific treatment (HSCT in particular) within 1 year before the SARS-CoV-2 diagnosis, concomitant infections, and lymphopenia. Data obtained in this study can help physicians with management decisions at this population of patients.

11 October 2026 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
ASA. V. Satsuk
A. V. Satsuk
GSGalina Solopova
Galina Solopova
SBS. V. Begunova
S. V. Begunova
ERE. V. Rozantseva
E. V. Rozantseva
OKO. S. Kozhushnaia
O. S. Kozhushnaia
ВАВ. Г. Акимкин
В. Г. Акимкин
The aim of the study was to conduct a retrospective analysis of the prevalence of markers for hepatitis B (HBV), hepatitis C (HCV), and HIV infection among patients in pediatric onco-hematology departments at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (hereinafter referred to as the Center) between 2013 and 2025, and to compare these findings with general population prevalence rates for chronic HBV, chronic HCV, and HIV infection. Materials and methods. A retrospective analysis was performed on the detection rates of markers for HBV, HCV, and HIV infection among onco-hematology patients aged 0—19 years treated at the Center between 2013 and 2025. A comparative analysis was conducted against the prevalence of these infections in the country's pediatric population during the period from 2013 to 2024. Testing for HBV markers was performed in 17,816 patients, for HCV markers in 17,762 patients, and for HIV infection markers in 17,741 patients. HBV markers were identified via HBsAg and/or HBV DNA testing; HCV markers via anti-HCV and/or HCV RNA testing; and HIV infection via immunoblotting results. Results. The mean detection rates for HBV, HCV, and HIV infection markers were 1.1%, 0.1%, and 0.1%, respectively, of all patients tested. A comparison of the detection rates of HBV, HCV, and HIV markers among pediatric patients in onco-hematology units with the prevalence of these infections in the country's pediatric population revealed rates that were 6, 45, and 3 times higher ( p < 0.001), respectively. Conclusions. Pediatric patients in onco-hematology units constitute a high-risk group for HBV, HCV, and HIV infections.

12 April 2026 in Sanitarnyj vrač (Sanitary Doctor)
Verified
Journal Article
Closed access
ASA. V. Satsuk
A. V. Satsuk
GSGalina Solopova
Galina Solopova
YRYulia Rodina
Yulia Rodina
SBS. V. Begunoba
S. V. Begunoba
ERE. V. Rozantseva
E. V. Rozantseva
VAVasily G Akimkin
Vasily G Akimkin
The aim of the study was to determine the incidence of occult hepatitis B in children with oncohematological diseases and primary immunodeficiency to evaluate the value of the anti-HBc marker for diagnosing occult hepatitis B. A retrospective analysis of the prevalence of hepatitis B virus (HBV) markers in children with oncohematological diseases was conducted. The study included 12,814 patients aged 18 years or younger (up to 21 years from September 1, 2022) treated at the «Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology» (hereinafter referred to as the Center) from 2018 to June 30, 2025. Patients were tested for the following infection markers: HBsAg (12,814 children), total anti-HBc (1,866 children), and HBV DNA (1,949 children). Anti-HBs antibodies were not measured. The prevalence of HBV infection in children with HBsAg or HBV DNA detection was 0.05 %. The prevalence of HBV markers HBsAg or HBV DNA or anti-HBc with combined detection was 1.0 %. Isolated anti-HBc was detected in 6.3 % of patients tested for this marker. No cases of seronegative occult hepatitis B were recorded. A statistically significant association was found between isolated anti-HBc and the administration of immunoglobulin preparations. The incidence of seronegative occult HBV (in the absence of HBsAg and anti-HBc) was 0 %. The presence of an isolated anti-HBc marker in the blood should not be considered seropositive for occult hepatitis B in immunocompromised children, as this marker may be transient in the presence of immunoglobulin replacement or immunomodulatory therapy.

14 April 2026 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
ASAnastasiia V. Satsuk
Anastasiia V. Satsuk
GSGalina Solopova
Galina Solopova
KKKaren Kyuregyan
Karen Kyuregyan
AKAnastasia Karlsen
Anastasia Karlsen
VKVera Sergeevna Kichatova
Vera Sergeevna Kichatova
СВСацук Анастасия Владимировна
Сацук Анастасия Владимировна
The aim of this study was to conduct an epidemiological analysis of hepatitis C infection in children with oncohematological diseases (OHD) using phylogenetic analysis of HCV nucleotide sequences and to analyze the causes and factors of HCV nosocomial transmission. Materials and methods. A retrospective analysis of HCV genetic isolates obtained from children with oncohematological diseases treated at the «Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology» (the Center) was conducted. The analysis included all children with HCV markers (anti-HCV and/or HCV RNA) identified between 2013 and 2025 during hospitalization and treatment at the Center—a total of 146 children. The children's ages ranged from 0 to 18 years, and from September 1, 2022, to 21 years. Samples were taken from the Center's bacteriology laboratory collection. Genotyping and phylogenetic analysis were performed at the Central Research Institute of Epidemiology of Rospotrebnadzor for 30 patient blood samples containing HCV RNA in quantities sufficient for analysis (at least 1000 IU/mL). To compare the distribution of HCV genotypes, the VGARus database data from 997 individuals was used. The core/E1 region of the HCV genome was sequenced and a phylogenetic analysis was performed. A Bayesian approach was used with the BEAST2 software package. The tree was visualized using FigTree. Results. In the structure of HCV genotypes isolated from children in the oncohematology departments, genotype 3a was predominant (77%), while 1b accounted for 23%. In contrast to the general population, where genotypes 3a and 1b circulate with equal frequency, the prevalence of genotype 3a among children with OHD indicates a greater involvement of this genotype in cases of nosocomial infection. Phylogenetic analysis revealed three common HCV clusters: 14 children with genotype 3a (13 children from the Amur Region and 1 child from the Altai Krai) and two common clusters with genotype 1b (2 patients each from the Kyrgyz Republic and Uzbekistan). The majority of HCV infection cases in children with OHD (60%) were nosocomial in origin. Cases of HCV infection in children from the Amur Region are associated with a long-standing chronic HCV epidemic in the oncohematology department of the Amur Regional Children's Clinical Hospital. No cases of infection have been identified at the Center. A patient from the Altai Krai region may have been infected at the Center in 2013-2014 during blood collection from a central venous catheter (CVC) due to improper hand sanitization, glove changing, aseptic technique, or work surface zoning. Standardization of procedures, implementation of aseptic non-touch technique (ANTT), training, and monitoring of staff knowledge and skills, widely implemented in the Center's work, have demonstrated high effectiveness, resulting in the absence of HCV transmission cases for over 10 years. Conclusion. Nosocomial HCV transmission in the OHD departments requires the widespread implementation of modern approaches to preventive and anti-epidemic measures, such as aseptic non-touch technique (ANTT), standardization of procedures, staff training, and knowledge and skills audits.

21 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AVA. O. Vereshchagina
A. O. Vereshchagina
GSGalina Solopova
Galina Solopova
TBT. A. Bykova
T. A. Bykova
MPMarina Popova
Marina Popova
DBD. N. Balashov
D. N. Balashov
GNG. A. Novichkova
G. A. Novichkova
The clinical course of the novel coronavirus disease (COVID-19) in patients with oncological and hematological diseases after hematopoietic stem cell transplantation (HSCT), are of special interest. To further investigate the problem, a two-center study was undertaken at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and the R.M. Gorbacheva National Research Institute for Pediatric Oncology, Hematology and Transplantation between January 2020 and January 2023. This was a retrospective-prospective, non-randomized, non-interventional study that included children aged 0–19 years with oncological and hematological diseases and primary immunodeficiencies who had undergone allogeneic HSCT and subsequently contracted COVID-19. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. COVID-19 cases were confirmed by polymerase chain reaction testing and classified as asymptomatic, mild, moderate, severe, and critical. The study included 105 patients with a median age of 9 years; male patients were predominant (the male-to-female ratio was 1.8:1). The primary diseases were hematological malignancies (73%), benign hematological diseases (14%) and primary immunodeficiencies (13%). The most common clinical symptoms of COVID-19 were fever, gastrointestinal symptoms, and respiratory symptoms; 40% of COVID-19 cases were asymptomatic. Lymphopenia was found to be a risk factor for severe COVID-19. The patients without immune reconstitution had a longer persistence of the COVID-19 virus than those with immune reconstitution (17 days versus 13 days), however, no significant differences were obtained (p = 0.7). There were also no significant differences in the severity and outcomes of COVID-19 between the patients with immune reconstitution and those without reconstitution. There was no effect of therapy on the duration of COVID-19, and there was no association between the type of treatment and the duration of the disease. The overall survival rate in the allo-HSCT recipients who had been diagnosed with COVID-19 was 88%, which was lower than in the non-recipients (88% vs 94%; p = 0,077).